VK3019 / Viking Therap - LARVOL DELTA

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults (PRNewswire) - "VK3019 is being developed as a potential treatment option for weight loss. The study initiation follows the filing and clearance of VK3019's investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). The Phase 1 trial is a randomized, double-blind, placebo-controlled SAD study in healthy adults with BMI ≥30. The primary objectives of the study include evaluating the safety, tolerability, and pharmacokinetics of single subcutaneous doses of VK3019. Exploratory pharmacodynamic assessments include evaluations of changes in body weight after a single-dose administration."

Trial status • Obesity

Pipeline and Recent Corporate Highlights (PRNewswire) - "Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled...Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26...VK2735 Maintenance Dosing Study Advances; Data Expected 3Q26....During the first quarter, the company filed an Investigational New Drug (IND) application for its lead amylin agonist VK3019. The company plans to initiate a Phase 1 trial evaluating VK3019 in 2Q26."

IND • New P1 trial • New P3 trial • P3 data • Obesity • Type 2 Diabetes Mellitus